We are excited to announce that PolTREG has launched Immuthera, a wholly owned subsidiary and a U.S. C Corporation registered in Delaware. This marks an important step in expanding our presence in the American market.

Immuthera will have full access to PolTREG’s extensive pipeline of cellular therapies, including polyclonal Tregs, CAR-TREGs, multi-edited/allogeneic CAR-Tregs, and antigen-specific Tregs, along with mRNA immunotherapies; all informed by PolTREG’s extensive clinical experience. Immuthera and PolTREG have partnered with NOBLE Capital Markets, Inc. for strategic and financial advisory services and formed a strategic alliance with Swiss company Antion Biosciences SA to develop next-generation allogeneic TREG therapies, said Prof. Piotr Trzonkowski, CEO of PolTREG and Immuthera.

Currently, Immuthera is in talks with leading U.S. academic and clinical centers to build collaborations and explore new technologies. Immuthera is also assembling a world-class Scientific Advisory Board with top experts in autoimmune and neuroinflammatory diseases.

Please find the whole press release here: https://www.globenewswire.com/news-release/2025/06/13/3099162/0/en/PolTREG-Establishes-U-S-Subsidiary-Immuthera-to-Advance-International-Development-Strategy.html